Eli Lilly Total Change in Assets/Liabilities 2010-2025 | LLY
Eli Lilly annual/quarterly total change in assets/liabilities history and growth rate from 2010 to 2025. Total change in assets/liabilities can be defined as the sum of all line items in the Asset/Liability section of the Cash Flows Statement
- Eli Lilly total change in assets/liabilities for the quarter ending June 30, 2025 was $-5.627B, a 78.62% increase year-over-year.
- Eli Lilly total change in assets/liabilities for the twelve months ending June 30, 2025 was $-14.142B, a 80.07% increase year-over-year.
- Eli Lilly annual total change in assets/liabilities for 2024 was $-5.385B, a 76.27% increase from 2023.
- Eli Lilly annual total change in assets/liabilities for 2023 was $-3.055B, a 381775% increase from 2022.
- Eli Lilly annual total change in assets/liabilities for 2022 was $-0.001B, a 99.92% decline from 2021.
Eli Lilly Annual Total Change in Assets/Liabilities
(Millions of US $) |
| 2024 |
$-5,385 |
| 2023 |
$-3,055 |
| 2022 |
$-1 |
| 2021 |
$-1,013 |
| 2020 |
$-747 |
| 2019 |
$-1,687 |
| 2018 |
$-2,379 |
| 2017 |
$3,205 |
| 2016 |
$-484 |
| 2015 |
$-1,139 |
| 2014 |
$-326 |
| 2013 |
$-393 |
| 2012 |
$-51 |
| 2011 |
$1,248 |
| 2010 |
$-186 |
| 2009 |
$-957 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$673.574B |
$45.043B |
|
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
|
